Accès ouvert
2026
article
OpenAlex
Eirini Vasarmidi, Diana Calaras, Ismini Kourouni, Apostolos Perelas et autres
Pulmonary Hypertension (PH) in patients with Interstitial Lung Disease (ILD) is a critical, yet underrecognized, complication that affects patients' quality of life and increases mortality. Emerging evidence further suggests that PH-ILD is not merely a consequence of hypoxia and parenchymal fibrosis, as …
gr, md, us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Maria Tziraki, Andreas M. Matthaiou, Manolis Linardakis, Eirini Vasarmidi et autres
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease which affects physical and mental well-being. The IPF Patient-Reported Outcome Measure (IPF-PROM) scale is a validated and reliable tool for the self-report of physical and psychological well-being in IPF. AIMS AND …
gr, gb, au
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Vasilina Sotiropoulou, Fotios Sampsonas, Eirini Vasarmidi, Katerina Antoniou et autres
Introduction Despite their profound clinical impact and high mortality, acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) still lack any effective or standardized treatment strategies. This manuscript describes the rationale and design of a randomized, multicenter, open-label Phase III clinical trial evaluating the …
gr, us, kw
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Katerina M. Antoniou, Eirini Vasarmidi, Alexandros Galaras, Marilena Lourou et autres
Survivors of COVID-19 can experience long-term lung complications. We compared bronchoalveolar lavage fluid (BALF) cells from patients who recovered from COVID-19 lung injury and those who experienced significant long term residual damage. A prominent gene expression profile of increased monocyte chemotaxis coupled …
gr, gb, au
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Nikoleta Bizymi, Andreas M. Matthaiou, AP Bizymis, Konstantina Symvoulaki et autres
Introduction and Objectives Myeloid-derived suppressor cells (MDSCs) are immature cells of the myeloid lineage with immunosuppressive properties, divided into polymorphonuclear and monocytic subpopulations, and are commonly involved in chronic inflammatory diseases. We aimed to systematically review the literature to assess the quantitative …
gr, cy
(code pays fourni par la source)
Accès ouvert
2025
editorial
OpenAlex
Eirini Vasarmidi, María Otaola, Pierre‐Antoine Juge
Qin et al. advanced SARD-ILD prognosis using CT radiomics to estimate disease severity. The GAP index (gender, age, pulmonary physiology) is a known mortality predictor in ILD (7). Their radiomics model accurately distinguished ILD-GAP stages (AUC > 0.8 across all cohorts). Unlike …
gr, ar, fr
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Izolde Bouloukaki, Michail Fanaridis, Vaia Stamatopoulou, Eirini Vasarmidi et autres
Background: Patients with COPD who suffer from OSA as a comorbidity (overlap syndrome-OVS) have a higher risk of exacerbations, hospitalization and cardiovascular (CVD) consequences. Aims and Objectives: To investigate the effect of Positive Airway Pressure (PAP) treatment on exacerbations and hospitalization rates, …
gr
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Nikoleta Bizymi, Andreas M. Matthaiou, Georgios Pitsidianakis, Anastasia C. Apostolidou et autres
Background: In the context of immune dysregulation accompanying bronchiectasis, myeloid-derived suppressor cells (MDSCs) are increased and correlated with neutrophilic inflammation and disease severity, while regulatory T cells (Tregs) are exhausted, probably predisposing to exacerbations. However, adaptive immunity in bronchiectasis, especially in relation …
gr
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Eirini Vasarmidi, Eliza Tsitoura, Marilena Lourou, Ioanna Argyriou et autres
Background: Unclassifiable interstitial lung disease (uILD) is a heterogeneous group of lung diseases, in which a definite diagnosis cannot be made, even after a multi-disciplinary team discussion. Unclassifiable disease may be found in up to 20% of ILD patients representing a challenging …
gr
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Eliza Tsitoura, Jannis Bastian Spintge, Eirini Vasarmidi, Ioanna Argyriou et autres
Interstitial lung disease (ILD) represents a heterogeneous group of lung disorders whose cellular and molecular mechanisms are incompletely understood. This clinical study aimed to elucidate underlying immune mechanisms at single-cell resolution focusing on alveolar macrophages and the periphery. A total of 44 …
gr, de, us, Égypte
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Katerina M. Antoniou, Ioanna Argyriou, Eirini Vasarmidi, Marilena Lourou et autres
Abstract Rationale The differential diagnosis of fibrotic interstitial lung diseases (ILDs) is complex, time consuming and costly and relies on a combination of tools, including chest high resolution computed tomography, blood tests, pulmonary function tests, bronchoscopy with lavage, and biopsies. Despite these …
gr, de
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Katerina M. Antoniou, Eirini Vasarmidi, Alexandros Galaras, Marilena Lourou et autres
Abstract Rationale/Aim: Survivors of COVID-19 can experience long-term lung complications (pulmonary sequelae), but the underlying mechanisms remain unclear. Our study aimed to analyse the bronchoalveolar lavage fluid (BALF) cell compartment of patients with post-COVID-19 ILD and address the question why some patients …
gr, gb
(code pays fourni par la source)